Ovid Therapeutics (OVID) Q4 2025 earnings summary

Executive summary

• OV329 advanced with strong safety and tolerability at up to 7 mg, supporting expansion into infantile spasms and tuberous sclerosis complex seizures, and best-in-category potential for refractory epilepsies.

• OV4071, a first-in-class oral KCC2 direct activator, received regulatory clearance for Phase 1 trials in Australia, targeting psychosis, neurodegenerative conditions, and rare epilepsies.

• Pipeline expansion enabled by $60 million PIPE/private placement financing and potential $53–$53.9 million from Series A warrant exercises, extending cash runway into late 2028 or 2029.

• New clinical programs launched in rare pediatric epilepsies and expansion of the KCC2 activator portfolio.

• Cash runway extended well into 2029 with PIPE financing and potential warrant exercises.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $90.4 million as of December 31, 2025, up from $53.1 million at year-end 2024.

• PIPE/private placement financing raised $60 million in gross proceeds, led by Point72.

• Full exercise of Series A warrants could provide an additional $53–$53.9 million.

• Revenue was $0.7 million for Q4 2025 and $7.3 million for FY 2025, including a one-time $7.0 million payment.

• Net income for Q4 2025 was $9.7 million, driven by a $21.0 million gain on long-term equity investment adjustment.

Outlook and guidance

• Phase II randomized placebo-controlled trial for OV329 in focal onset seizures to begin in Q2 2026, with additional studies in infantile spasms and TSC planned for late 2026 and 2027.

• OV4071 Phase I study to initiate in Q2 2026, followed by a ketamine challenge and proof-of-concept trials.

• Multiple clinical and regulatory milestones anticipated through 2027, with potential for accelerated registration and orphan status.

• Additional pediatric and rare disease programs to launch, with potential for combined pivotal phase II/III studies.